Aravive, Inc. – NASDAQ:ARAV

Financial Health
0
1
2
3
4
5
6
7
8
9

Aravive stock price monthly change

-68.82%
month

Aravive stock price quarterly change

-70.80%
quarter

Aravive stock price yearly change

-97.66%
year

Aravive key metrics

Market Cap
2.94M
Enterprise value
14.76M
P/E
-0.84
EV/Sales
1.24
EV/EBITDA
-0.13
Price/Sales
5.43
Price/Book
6.04
PEG ratio
0.10
EPS
-1.17
Revenue
6.99M
EBITDA
-84.23M
Income
-81.15M
Revenue Q/Q
-44.39%
Revenue Y/Y
-19.11%
Profit margin
-910.64%
Oper. margin
-888.74%
Gross margin
0%
EBIT margin
-888.74%
EBITDA margin
-1204.2%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Aravive stock price history

Aravive stock forecast

Aravive financial statements

Aravive, Inc. (NASDAQ:ARAV): Profit margin
Dec 2022 1.47M -38.38M -2604.14%
Mar 2023 1.49M -81.99M -5499.6%
Jun 2023 1.27M 18.00M 1413.5%
Sep 2023 2.75M 21.22M 770.17%
Aravive, Inc. (NASDAQ:ARAV): Analyst Estimates
2025 1.46M -24M -1636.36%
  • Analysts Price target

  • Financials & Ratios estimates

Aravive, Inc. (NASDAQ:ARAV): Debt to assets
Dec 2022 62153000 51.49M 82.85%
Mar 2023 43044000 81.65M 189.7%
Jun 2023 25737000 45.55M 177%
Sep 2023 13049000 11.34M 86.96%
Aravive, Inc. (NASDAQ:ARAV): Cash Flow
Dec 2022 -14.23M -11K 40.04M
Mar 2023 -17.75M 0 0
Jun 2023 -17.65M 0 25K
Sep 2023 -9.80M 0 25K

Aravive alternative data

Aravive, Inc. (NASDAQ:ARAV): Employee count
Aug 2023 23
Sep 2023 23
Oct 2023 23
Nov 2023 23
Dec 2023 23
Jan 2024 23
Feb 2024 23
Mar 2024 23
Apr 2024 23
May 2024 23
Jun 2024 23
Jul 2024 23

Aravive other data

100.00% 0.00%
of ARAV is owned by hedge funds
6.29M -8.91M
shares is hold by hedge funds

Aravive, Inc. (NASDAQ:ARAV): Insider trades (number of shares)
Period Buy Sel
Dec 2020 16000 0
Jun 2021 2000 0
Nov 2021 0 3245
Transaction Date Insider Security Shares Price per share Total value Source
Option
ESHELMAN FREDRIC N other: See Footnote (1)
Pre-Funded Warrant (right to buy) 4,545,455 N/A N/A
Option
ESHELMAN FREDRIC N other: See Footnote (1)
Common Stock 4,545,455 N/A N/A
Option
GIACCIA AMATO director
Stock Option 39,261 $0.24 $9,423
Sale
GIACCIA AMATO director
Common Stock 3,245 $3.22 $10,449
Option
GIACCIA AMATO director
Common Stock 51,611 $0.18 $9,290
Purchase
SHAH VINAY officer: Chief Financial Officer
Common Stock 1,000 N/A N/A
Purchase
MCINTYRE GAIL FRANCES director, officer: CEO and Pres..
Common Stock 1,000 N/A N/A
Option
GIACCIA AMATO director
Common Stock 12,083 N/A N/A
Option
GIACCIA AMATO director
Stock Option (Right to buy) 8,055 N/A N/A
Purchase
SHAH VINAY officer: Chief Financial Officer
Common Stock 8,000 $5.76 $46,080
Insider Compensation
Dr. Gail F. McIntyre CH (ASCP), DABT, Ph.D. (1963) Pres, Chief Executive Officer & Director
$562,470
Mr. Vinay Shah MBA (1963) Chief Financial Officer
$481,990
Dr. Reshma Rangwala M.D., Ph.D. (1978) Chief Medical Officer $455,810
Thursday, 18 January 2024
investorplace.com
proactiveinvestors.com
Wednesday, 17 January 2024
globenewswire.com
Friday, 13 October 2023
Zacks Investment Research
Monday, 21 August 2023
Zacks Investment Research
Thursday, 3 August 2023
InvestorPlace
Friday, 28 July 2023
GlobeNewsWire
Thursday, 15 June 2023
InvestorPlace
Monday, 5 June 2023
GlobeNewsWire
Thursday, 25 May 2023
GlobeNewsWire
Thursday, 18 May 2023
InvestorPlace
Monday, 17 April 2023
Zacks Investment Research
Sunday, 16 April 2023
InvestorPlace
Thursday, 30 March 2023
InvestorPlace
Wednesday, 15 March 2023
Zacks Investment Research
Sunday, 26 February 2023
Seeking Alpha
Thursday, 23 February 2023
PennyStocks
Monday, 13 February 2023
GlobeNewsWire
Wednesday, 14 December 2022
Seeking Alpha
Thursday, 10 November 2022
Zacks Investment Research
Wednesday, 2 November 2022
PennyStocks
Monday, 31 October 2022
PennyStocks
Tuesday, 6 September 2022
GlobeNewsWire
Thursday, 11 August 2022
Zacks Investment Research
Tuesday, 17 May 2022
GlobeNewsWire
Thursday, 12 May 2022
Zacks Investment Research
Thursday, 31 March 2022
Zacks Investment Research
Thursday, 3 March 2022
Benzinga
Wednesday, 2 March 2022
GlobeNewsWire
Thursday, 10 February 2022
Zacks Investment Research
  • When is Aravive's next earnings date?

    Unfortunately, Aravive's (ARAV) next earnings date is currently unknown.

  • Does Aravive pay dividends?

    No, Aravive does not pay dividends.

  • How much money does Aravive make?

    Aravive has a market capitalization of 2.94M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 22.78% to 9.14M US dollars.

  • What is Aravive's stock symbol?

    Aravive, Inc. is traded on the NASDAQ under the ticker symbol "ARAV".

  • What is Aravive's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Aravive?

    Shares of Aravive can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Aravive's key executives?

    Aravive's management team includes the following people:

    • Dr. Gail F. McIntyre CH (ASCP), DABT, Ph.D. Pres, Chief Executive Officer & Director(age: 62, pay: $562,470)
    • Mr. Vinay Shah MBA Chief Financial Officer(age: 62, pay: $481,990)
    • Dr. Reshma Rangwala M.D., Ph.D. Chief Medical Officer(age: 47, pay: $455,810)
  • How many employees does Aravive have?

    As Jul 2024, Aravive employs 23 workers.

  • When Aravive went public?

    Aravive, Inc. is publicly traded company for more then 11 years since IPO on 21 Mar 2014.

  • What is Aravive's official website?

    The official website for Aravive is aravive.com.

  • Where are Aravive's headquarters?

    Aravive is headquartered at River Oaks Tower, Houston, TX.

  • How can i contact Aravive?

    Aravive's mailing address is River Oaks Tower, Houston, TX and company can be reached via phone at +93 63551910.

Aravive company profile:

Aravive, Inc.

aravive.com
Exchange:

NASDAQ

Full time employees:

23

Industry:

Biotechnology

Sector:

Healthcare

Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a strategic collaboration agreement with WuXi Biologics (Hong Kong) Limited to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.

River Oaks Tower
Houston, TX 77098

CIK: 0001513818
ISIN: US03890D1081
CUSIP: 03890D108